No Data
Celldex Therapeutics Initiates Phase 2 Study of Barzolvolimab for Atopic Dermatitis Treatment
Celldex Launches Phase 2 Study Of Barzolvolimab For Atopic Dermatitis, Targeting Mast Cell-Driven Inflammation And Epithelial Barrier Dysfunction With Patient Enrollment Underway
Express News | Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis
Celldex Therapeutics Initiates Phase 1a Trial for Bispecific Antibody CDX-622 Targeting Chronic Inflammation
Express News | Celldex Therapeutics Inc - Subcutaneous Formulation to Be Added to Study in 2025
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
No Data
